AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02431975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices.
Study NCT02431975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices.
Study NCT02431975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices.
Study NCT03551652 — intervention group
Intervention type: DRUG
Intervention: Pharmacokinetics of rocuronium induced neuromuscular block
Description: Measurement of rocuronium induced neuromuscular block comparing patients aged > 80 years with patients aged 18 to 50 years
Study NCT04157244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored music listening intervention
Description: The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
Study NCT01025713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411
Study NCT01025713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study NCT00600600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Tigecycline dosage based on age and clinical status of patient.
Study NCT01682278 — intervention group
Intervention type: DEVICE
Intervention: Removal of dental amalgam restorations
Description: Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient.
Study NCT04561570 — intervention group
Intervention type: DEVICE
Intervention: Vivity ACRYSOF IQ IOL Group
Description: Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
Study NCT04561570 — intervention group
Intervention type: DEVICE
Intervention: ACRYSOF IQ IOL Control Group
Description: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
Study NCT00681317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: oral
Study NCT03849170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Technique
Description: Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
Study NCT03849170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Intervention
Description: Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
Study NCT02524665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Cleanser
Description: Available over the counter.
Study NCT02524665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Treatment
Description: Available over the counter.
Study NCT02524665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Description: Available over the counter.
Study NCT02524665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MURAD Clarifying Cleanser (1.5% SA)
Description: Available over the counter.
Study NCT02524665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exfoliating Acne Treatment Gel (1% SA)
Description: Available over the counter.
Study NCT02524665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin Perfecting Lotion
Description: Available over the counter.
Study NCT04900415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Metabolic supplement for neurogenesis at the olfactory apparatus
Study NCT04900415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic portable aromatic rehabilitation (EPAR) diffuser
Description: Handheld essential oil ultrasonication diffuser technology
Study NCT04900415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic portable aromatic rehabilitation (EPAR) diffuser
Description: Handheld essential oil ultrasonication diffuser technology
Study NCT02441179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
Study NCT02441179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body weight-assisted treadmill training
Description: Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
Study NCT02441179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Body weight-assisted treadmill training
Description: Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
Study NCT02441179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Protocol
Description: It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
Study NCT00960310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
Study NCT00960310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
Study NCT04363931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
Study NCT04363931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
Study NCT00653887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: 4 sessions of biofeedback one session each week
Study NCT00653887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 sessions, one each week, of discussion about anorectal disease
Study NCT00295620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg tablet daily
Study NCT02163694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veliparib Placebo
Description: Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
Study NCT02163694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
Study NCT02163694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
Study NCT02163694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
Study NCT02163694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
Study NCT02163694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
Study NCT04508621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Study NCT04508621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Study NCT00057785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
Study NCT00057785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
Study NCT00057785 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
Study NCT01636310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
Study NCT03856346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biometry
Description: Biometry for phaco-vitrectomy procedures pre- and postoperatively
Study NCT01494649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Toothpaste
Description: 0.454% stannous fluoride toothpaste
Study NCT01494649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Negative Control Toothpaste
Description: 0.76% sodium monofluorophosphate toothpaste
Study NCT02735226 — intervention group
Intervention type: OTHER
Intervention: stroke network and policy intervention
Description: Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
Study NCT03430557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma
Study NCT03430557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery without PRP
Description: retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
Study NCT04061057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min.
Study NCT04061057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min.
Study NCT02816749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maggot debridement therapy
Description: Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
Study NCT02816749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing Therapy
Description: Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
Study NCT00965263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cocaine vaccine (TA-CD)
Description: TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
Study NCT00861939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCI 300 mg Extended-Release Tablets EON
Study NCT00861939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
Study NCT03199898 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Silverman-Andersen Retraction Score
Description: The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
Study NCT03013517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250µg
Description: DBV712 250 µg, once daily
Study NCT00893230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic L sakei KCTC 10755BP
Description: freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
Study NCT00786357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIOSH shiftwork booklet
Description: weekly readings about coping with shiftwork
Study NCT00786357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Enhancement Training System
Description: 4 week program of readings and relaxation programs
Study NCT02811237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HESTIA
Description: Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.
Study NCT02811237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sPESI
Description: Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF.
Study NCT00893230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose (placebo)
Description: freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
Study NCT01999322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study NCT01999322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study NCT00591292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: Dose escalation of indibulin given twice daily for up to 6 months
Study NCT00668109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg one hour prior to sexual intercourse
Study NCT00668109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: 10 mg taken approximately 24 hours prior to sexual intercourse
Study NCT03701555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP001 placebo
Description: placebo
Study NCT00866528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral pazopanib once daily (Phase I starting dose 800 mg)
Study NCT00866528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
Study NCT00190684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: 0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
Study NCT00423228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-1
Description: Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
Study NCT00423228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
Study NCT02738489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A fully human monoclonal immunoglobulin (IgG4 subtype)
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 100 mg
Description: PvP001 100 mg
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 300 mg
Description: PvP001 300 mg
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 900 mg
Description: PvP001 900 mg
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Feasible Dose (MFD) of PvP002
Description: MFD of PvP002
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Tolerated Dose (MTD) of PvP001
Description: Maximum Tolerated Dose (MTD) of PvP001
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTD of PvP001 following 7 days of PPI treatment
Description: Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
Study NCT03701555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PvP002 placebo
Description: Placebo
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP001 600 mg
Description: PvP001 600 mg
Study NCT03701555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PvP003 placebo
Description: Placebo tablet orally.
Study NCT02069886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: 125, 250, 500 mg dispersable tablets